

## COVAX plans global rollout of COVID-19 vaccine starting Q1 2021

21 December 2020 | News

**Nearly two billion doses of several promising vaccine candidates can be accessed now from all COVAX's 190 participating and eligible economies to protect vulnerable groups in the first half of 2021**



COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income level, has announced that it had arrangements in place to access nearly two billion doses of COVID-19 vaccine candidates, on behalf of 190 participating economies.

For the vast majority of these deals, COVAX has guaranteed access to a portion of the first wave of production, followed by volume scales as further supply becomes available. The arrangements will enable all participating economies to have access to doses in the first half of 2021, with first deliveries anticipated to begin in the first quarter of 2021 – contingent upon regulatory approvals and countries' readiness for delivery.

Given these are arrangements for 2 billion doses of vaccine candidates which are still under development, COVAX will continue developing its portfolio: this will be critical to achieve its goal of securing access to 2 billion doses of safe and effective, approved vaccines that are suitable for all participants' contexts, and available by the end of 2021. This includes delivering at least 1.3 billion donor-funded doses of approved vaccines in 2021 to the 92 low- and middle-income economies eligible for the COVAX AMC.

The new deals include the signing of an advance purchase agreement with AstraZeneca for 170 million doses of the AstraZeneca/Oxford candidate, and a memorandum of understanding (MoU) with Johnson & Johnson for 500 million doses of the Janssen candidate, which is currently being investigated as a single dose vaccine.. These deals are in addition to existing agreements COVAX has with the Serum Institute of India (SII) for 200 million doses – with options for up to 900 million doses more – of either the AstraZeneca/Oxford or Novavax candidates, as well as a statement of intent for 200 million doses of the Sanofi/GSK vaccine candidate.

In addition to this, COVAX also has – through R&D partnership agreements – first right of refusal in 2021 to access potentially more than one billion doses (based on current estimates from the manufacturing processes under development)

that will be produced, subject to technical success and regulatory approval, by candidates in the COVAX R&D Portfolio.

**List of deals that have so far been secured by COVAX on behalf of the Facility**

- 170 million doses of the AstraZeneca/Oxford candidate, via an advance purchase agreement between Gavi and AstraZeneca, and enabled by a partnership agreement with CEPI to fund scale-out of manufacturing
- 200 million doses (and options for up to 900 million more) of the AstraZeneca/Oxford or Novavax candidates, via an agreement between Gavi, the Serum Institute of India, and the Bill and Melinda Gates Foundation
- 500 million doses of the Janssen candidate, via a memorandum of understanding with Johnson & Johnson
- 200 million doses of the Sanofi/GSK vaccine candidate, via a statement of intent between Gavi, Sanofi and GSK
- First right of refusal for a potential combined total of over 1 billion doses in 2021 (based on current estimates from the manufacturing processes under development) of promising vaccine candidates, via R&D partnership agreements with CEPI - that will be produced, subject to technical success and regulatory approval, by candidates in the COVAX R&D Portfolio.